Chronic Hepatitis News

Replicor recently shared follow-up data from the ongoing REP 401 trial that showed high rates of persistent functional control of hepatitis B after cessation of therapy with REP 2139-Mg or REP 2165-Mg plus pegylated interferon alpha-2a and tenofovir disoproxil fumarate, according to a press release.

WASHINGTON — Researchers identified a cohort of homeless veterans who successfully completed hepatitis C treatment and achieved sustained virologic response, including patients with polysubstance use, according to a presentation at Digestive Disease Week 2018.

Despite the availability of highly effective direct-acting antiviral therapy for chronic hepatitis C virus infection, both public and private health insurers in the United States continue to deny coverage for the drugs at increasingly high rates, according to a study published today in Open Forum Infectious Diseases.

WASHINGTON — In this exclusive video perspective from Digestive Disease Week 2018, Steven L. Flamm, MD, chief of the Liver Program at Northwestern University Feinberg School of Medicine in Illinois, reviews some of the important clinical presentations in liver disease from the meeting.

The Canadian Association for the Study of the Liver, or CASL, released a guideline today that now recommends screening patients born between 1945 and 1975 for hepatitis C virus.

WASHINGTON — In this exclusive video perspective from Digestive Disease Week 2018, Zobair M. Younossi, MD, chairman of the department of medicine at Inova Fairfax Hospital in Virginia, discusses insurance coverage and mortality in patients with hepatitis C in the U.S.

The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America recently updated their hepatitis guideline website, HCVguidelines.org, to include several new testing and management recommendations for pregnant women, men who have sex with men, people who inject drugs and incarcerated individuals.

As Hepatitis Awareness Month comes to a close, Healio.com/Hepatology presents several recently published studies on hepatitis B therapy outcomes and expert opinions on hepatitis awareness in both the public and clinical domains.

Quantification of antibody against hepatitis B core protein, or anti-HBc levels, significantly predicted HBV surface antigen seroclearance and undetectable HBV DNA in treatment-naive patients with chronic HBV who are HBV e antigen-seronegative, according to a recently published study.

Patients with hepatitis B-related decompensated cirrhosis who achieved virologic response after treatment with either Baraclude or Epivir had significantly improved long-term and transplant-free survival, according to results of a 10-year observational study.